Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Padmanee Sharma

Showing results (131-140 of 216) with videos related to

Pageof 22
Sort By:
Journal for Immunotherapy of Cancer|August 16, 2017
Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinomaAshish M Kamat, Joaquim Bellmunt, Matthew D Galsky, et al.
European Urology|March 7, 2017
CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell CarcinomaBernard Escudier, Padmanee Sharma, David F McDermott, et al.
Science Translational Medicine|April 3, 2020
Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancerSumit K Subudhi, Luis Vence, Hao Zhao, et al.
Journal for Immunotherapy of Cancer|July 30, 2021
Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse eventsBilal A Siddiqui, Jinesh S Gheeya, Rohit Goswamy, et al.
European Urology|January 8, 2018
Erratum to "CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma" [Eur Urol 2017;72:962-71]Bernard Escudier, Padmanee Sharma, David F McDermott, et al.
Cancer Immunology Research|May 28, 2015
Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell CarcinomaXian-De Liu, Anh Hoang, Lijun Zhou, et al.
Nature Communications|August 31, 2018
EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancerLi Wang, Abdel Saci, Peter M Szabo, et al.
Cancer Immunology Research|March 25, 2025
Mesenchymal Stem Cells and Fibroblasts Contribute to Microvascular Proliferation in Glioblastoma and are Correlated with Immunosuppression and Poor OutcomeCandice C Poon, Shelley M Herbrich, Yulong Chen, et al.
NPJ Precision Oncology|May 20, 2025
Multimodal spatial proteomic profiling in acute myeloid leukemiaChristopher P Ly, Ivo Veletic, Christopher D Pacheco, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2021
Myeloid Cell-associated Resistance to PD-1/PD-L1 Blockade in Urothelial Cancer Revealed Through Bulk and Single-cell RNA SequencingLi Wang, John P Sfakianos, Kristin G Beaumont, et al.
Pageof 22

Showing results (131-140 of 216) with videos related to

Sort By:
Pageof 22
Journal for Immunotherapy of Cancer|August 16, 2017
Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinomaAshish M Kamat, Joaquim Bellmunt, Matthew D Galsky, et al.
European Urology|March 7, 2017
CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell CarcinomaBernard Escudier, Padmanee Sharma, David F McDermott, et al.
Science Translational Medicine|April 3, 2020
Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancerSumit K Subudhi, Luis Vence, Hao Zhao, et al.
Journal for Immunotherapy of Cancer|July 30, 2021
Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse eventsBilal A Siddiqui, Jinesh S Gheeya, Rohit Goswamy, et al.
European Urology|January 8, 2018
Erratum to "CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma" [Eur Urol 2017;72:962-71]Bernard Escudier, Padmanee Sharma, David F McDermott, et al.
Cancer Immunology Research|May 28, 2015
Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell CarcinomaXian-De Liu, Anh Hoang, Lijun Zhou, et al.
Nature Communications|August 31, 2018
EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancerLi Wang, Abdel Saci, Peter M Szabo, et al.
Cancer Immunology Research|March 25, 2025
Mesenchymal Stem Cells and Fibroblasts Contribute to Microvascular Proliferation in Glioblastoma and are Correlated with Immunosuppression and Poor OutcomeCandice C Poon, Shelley M Herbrich, Yulong Chen, et al.
NPJ Precision Oncology|May 20, 2025
Multimodal spatial proteomic profiling in acute myeloid leukemiaChristopher P Ly, Ivo Veletic, Christopher D Pacheco, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2021
Myeloid Cell-associated Resistance to PD-1/PD-L1 Blockade in Urothelial Cancer Revealed Through Bulk and Single-cell RNA SequencingLi Wang, John P Sfakianos, Kristin G Beaumont, et al.
Pageof 22